SOAP II Trial: Shaping Vasopressor Choice in Septic Shock

Why SOAP II Remains Important

Septic shock requires timely resuscitation, and vasopressor selection is a critical piece of management. The SOAP II trial (Sepsis Occurrence in Acutely Ill Patients II) remains one of the most influential studies comparing dopamine and norepinephrine as first-line vasopressors. Its findings directly impacted guidelines and continue to inform everyday decisions in emergency and critical care.

Evidence to Date

SOAP II demonstrated that dopamine and norepinephrine produced similar mortality outcomes in septic shock, but dopamine carried a higher risk of arrhythmias. Since publication, most international guidelines have endorsed norepinephrine as the initial vasopressor of choice. Dopamine is still occasionally considered in patients with bradycardia or certain cardiogenic shock presentations, but it is rarely the default. The trial is frequently cited in discussions of resuscitation strategy and remains foundational in sepsis education.

Ongoing Debates and Research

Subsequent research has focused on alternatives and adjuncts, including vasopressin and epinephrine, as well as individualized strategies based on shock phenotype. Some investigators argue that fluid responsiveness and microcirculatory assessments should also guide vasopressor choice. Nonetheless, the lesson from SOAP II—that norepinephrine offers greater safety and comparable efficacy—remains widely applicable. Current debates focus less on whether norepinephrine is superior and more on when and how to escalate beyond it.

Clinical Guidance for Physicians

Norepinephrine should be the first-line vasopressor in septic shock, initiated promptly once adequate fluid resuscitation has been attempted. Dopamine has a limited role, primarily in specific patient subsets, and should be used cautiously. Physicians must remain vigilant for arrhythmias and consider the evolving hemodynamic picture.

Bottom Line

The SOAP II trial continues to shape septic shock management by reinforcing norepinephrine as the safest and most effective first-line vasopressor. Its influence is evident in both bedside decisions and global guidelines, underscoring the importance of evidence-based resuscitation strategies.

Click here to learn more about the SOAP II trial as part of our Classics Series

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.